SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001562180-24-002846
Filing Date
2024-03-19
Accepted
2024-03-19 19:26:45
Documents
2
Period of Report
2024-03-10

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 3  
1 PRIMARY DOCUMENT primarydocument.xml 3 5582
2 POA_KURIAKOSE poa_kuriakose.txt EX-24 5487
  Complete submission text file 0001562180-24-002846.txt   12536
Mailing Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404
Business Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404 650-525-5535 EXT.101
Terns Pharmaceuticals, Inc. (Issuer) CIK: 0001831363 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 343 OYSTER POINT BLVD, SUITE 200 SOUTH SAN FRANCISCO CA 94080
Business Address
Kuriakose Emil (Reporting) CIK: 0001892413 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39926 | Film No.: 24765740